Consumer education is an integral part of the European Community's consumer policy. It plays a key role in consumer empowerment, helping consumers gain the skills, attitudes and knowledge they need to be able to gear the choices they make as consumers to their economic interests and to protect their health and safety. In its policy statement, the Directorate General for Health and Consumer Protection states that the European Community is aware that joint measures at national and Community levels should be more structured, in order to achieve maximum effectiveness. This paper aims to set out the current policy and strategic context for consumer education and empowerment in the UK; review the role of UK government bodies and other agencies concerned with developments; review recent literature; present the results of interviews with an extensive range of key stakeholders and the results of a survey of service heads for trading standards throughout the UK. It will consider implementation, partnership, resources, ideas and opportunities. The research found that the agenda for consumer education in the UK is at an interesting stage of development. The Enterprise Act 2002 gives the Office of Fair Trading (OFT) a statutory power to carry out educational activities. Consumer education is also moving up the agenda in the trading standards service. In addition, the teaching of citizenship in English schools is already stimulating new developments in consumer education. The paper will consider the need for organizations like these to work together to build on these policy developments and ensure that consumer education gains the profile it needs to influence consumer attitudes and behaviour. 相似文献
This article addresses the connection of ethics to risk management, and argues that there are compelling reasons to consider good ethical practice to be an essential part of such risk management. That connection has significant commercial outcomes, which include identifying potential problems, preventing fraud, the preservation of corporate reputation, and the mitigation of court penalties should any transgression arise. Information about the legal position, examples of cases, and arguments about the potential benefits of ethics are canvassed. The orientation of this article is essentially Australian. It is hoped that it may provide some insights of value to other countries. 相似文献
This article examines the implications of “prominence” in search markets. We model prominence by supposing that the prominent firm will be sampled first by all consumers. If there are no systematic quality differences among firms, we find that the prominent firm will charge a lower price than its less prominent rivals. Making a firm prominent will typically lead to higher industry profit but lower consumer surplus and welfare. The model is extended by introducing heterogeneous product qualities, in which case the firm with the highest‐quality product has the greatest incentive to become prominent, and making it prominent will boost industry profit, consumer surplus, and welfare.相似文献
We provide a framework for analyzing two-sided markets that allows for different degrees of product differentiation on each
side of the market. When platforms are viewed as homogenous by sellers but heterogeneous by buyers, we show that “competitive
bottlenecks” arise endogenously. In equilibrium, platforms do not compete directly for sellers, instead choosing to compete
indirectly by subsidizing buyers to join. Sellers are left with none of the gains from trade. Despite this, it is sellers
who choose to purchase from multiple platforms (multihome). Finally, the role of exclusive contracts to prevent multihoming
is explored.
We are very grateful to Jose Miguel Abito for research assistance, and to the editor and a referee for helpful comments. 相似文献
AbstractBackground: Injectable botulinum neurotoxins are a mainstay of treatment for pediatric spasticity. AbobotulinumtoxinA and onabotulinumtoxinA are both injectable toxin therapies used to treat pediatric lower limb (PLL) spasticity in Canada. The objective of this study was to assess the cost-effectiveness of abobotulinumtoxinA vs. onabotulinumtoxinA in the treatment of PLL spasticity in Canada.Methods: A probabilistic Markov cohort model with a 2-year time horizon was developed, with health states defined by response to therapy, as characterized by the goal attainment scale (GAS). Based on randomized controlled trial evidence, response to therapy was similar or higher for abobotulinumtoxinA relative to onabotulinumtoxinA; uncertainty was incorporated into model parameters, however, as the two therapies have not been compared head-to-head. Canadian resource use and cost data were incorporated.Results: In the base case, abobotulinumtoxinA generated 1.48 quality-adjusted life years over the model time horizon, compared to 1.47 for onabotulinumtoxinA. AbobotulinumtoxinA was associated with cost savings of $123 CAD, reflecting lower costs in both medication acquisition and health services. The estimated improvement to quality of life and reduced costs result in an estimate of economic dominance for abobotulinumtoxinA over onabotulinumtoxinA. This dominant result persisted across probabilistic and scenario analyses.
Key points for decision makers
Based on a review of available clinical evidence, abobotulinumtoxinA was found to have significant and/or numerical efficacy benefits to onabotulinumtoxinA on functional outcomes (Goal Attainment Scale) and tone (Modified Ashworth Scale) and in the treatment of pediatric lower limb spasticity
In this cost-effectiveness analysis, abobotulinumtoxinA was found to be associated with greater quality-adjusted life years and lower costs than onabotulinumtoxinA (economically dominant)
A limitation of this analysis was the uncertainty around key parameters. Specifically, the lack of head-to-head comparison data for the two therapies, and variable data regarding likely onabotulinumtoxinA dosing in PLL in clinical practice. However, across a range of plausible scenarios, the economic dominant result remained.
By the 1970s the Australian manufacturing sector was, by OECD standards, small, fragmented and inward looking. Successive Australian Federal Governments have since responded by progressively reducing levels of assistance to manufacturing in an effort to promote structural change. In this article we investigate whether these lower levels of assistance have accelerated the pace of structural change by estimating an empirical model using a pooled cross-section time-series data set. Our results suggest that reduced levels of assistance to manufacturing have had a positive impact on the pace of structural change in the Australian manufacturing sector. In addition, we find that taxes on factor inputs can be expected to impede structural change, and it would appear that structural change proceeds at a faster pace in more specialised manufacturing sectors. 相似文献
This paper discusses the scope for competition in the telecommunicationsindustry, taking into account the features of natural monopoly,network externalities, and customer inertia. Recent policy towardscompetition in the industry in the UK is surveyed, with an emphasison access pricing and interconnection. Finally, recent theoreticaldevelopments in the economics of access pricing and interconnectionare discussed and shown to lend some support for aspects ofcurrent policy in the UK. 相似文献
Arrow's Theorem is shown to be valid for measurable spaces of economic agents even with only a Boolean algebra of measurable coalitions. Purely competitive social welfare functions which ignore negligible coalitions may be handled by passing to a Boolean quotient algebra with the ideal of negligible coalitions. Invisible dictators are ‘agents’ in the Stone space of the quotient algebra, in which context social welfare functions induce continuous preference profiles. 相似文献